Physician profile
Leandra Smith
NPI 1154966703
$405.25
in general payments reported to CMS, 2019-2025
14 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.80 · 2022: $14.05 · 2023: $47.10 · 2024: $166 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $350.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $79.43 | 2023-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Lilly USA, LLC | $58.07 | 2021-2024 | Mounjaro, Zepbound, Trulicity |
| Corcept Therapeutics | $37.00 | 2024 | Korlym |
| Exact Sciences Corporation | $35.31 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $34.55 | 2024-2025 | |
| Genentech USA, INC. | $25.41 | 2021 | |
| Vanda Pharmaceuticals INC. | $23.81 | 2025 | Fanapt |
| Novo Nordisk INC | $22.63 | 2024 | |
| Merck Sharp & Dohme LLC | $16.32 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Phadia US INC. | $15.59 | 2025 | Immunocap |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.88 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $14.66 | 2025 | Auvelity |
| Vbi Vaccine (Delaware) INC. | $14.05 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.54 | 2025 | Uzedy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leandra Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.